Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)

OBJECTIVE: This study aims to assess the efficacy and safety of penpulimab (a humanized anti-PD-1 IgG1 antibody) with anlotinib in the first-line treatment of Chinese patients with uHCC. METHODS: In this open-label multicenter phase Ib/II trial, patients with histologically or cytologically confirme...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Chun, Ye, Sisi, Hu, Chunhong, Shen, Liangfang, Qin, Qun, Bai, Yuxian, Yang, Shizhong, Bai, Chunmei, Zang, Aimin, Jiao, Shunchang, Bai, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313824/
https://www.ncbi.nlm.nih.gov/pubmed/34327136
http://dx.doi.org/10.3389/fonc.2021.684867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313824/
https://www.ncbi.nlm.nih.gov/pubmed/34327136
http://dx.doi.org/10.3389/fonc.2021.684867

Ejemplares similares